Fazirsiran

RNA / oligonucleotide

Phase 3underway

Evidence outlook · registrational

Alpha-1 Antitrypsin Deficiency: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2028-08-26.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Alpha-1 Antitrypsin Deficiency
NCT05899673 · Takeda
2023-08-08 – 2033-05-02 · Alpha1-Antitrypsin Deficiency
What this study did
Phase 2 (2)
Alpha-1 Antitrypsin Deficiency
NCT03946449 · Arrowhead Pharmaceuticals
2019-10-31 – 2023-12-14 · Alpha 1-Antitrypsin Deficiency
What this study did
NCT03945292 · Arrowhead Pharmaceuticals
2019-08-07 – 2023-09-18 · Alpha 1-Antitrypsin Deficiency
What this study did
Phase 1 (2)
Alpha-1 Antitrypsin Deficiency
NCT03362242 · Arrowhead Pharmaceuticals
2018-03-12 – 2020-03-21 · Alpha 1-Antitrypsin Deficiency
What this study did
Other / comorbidity
NCT05891158 · Takeda
2023-10-05 – 2025-09-03 · Hepatic Impairment
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Alpha-1 Antitrypsin Deficiency: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fazirsiran: this drugPhase 3RNA / oligonucleotideSERPINA1not yet gradedNo reviewed efficacy summary in this indication
AlvelestatPhase 2Small moleculeNeutrophil elastasePartial signal
NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively).
BEAM-302Phase 1/2Gene therapy / editingSERPINA1 PiZ mutation (E342K)not yet gradedNo reviewed efficacy summary in this indication
TSRA-196Phase 1/2Gene therapy / editingSERPINA1not yet gradedNo reviewed efficacy summary in this indication
WVE-006Phase 1/2RNA / oligonucleotideSERPINA1 Z-allele mRNA (ADAR-mediated editing)not yet gradedNo reviewed efficacy summary in this indication
KB408Phase 1Gene therapy / editingSERPINA1 (alpha-1 antitrypsin; gene replacement)not yet gradedNo reviewed efficacy summary in this indication
Efdoralprin Alfa
—(overall)
Protein / enzyme therapeuticAlpha-1 antitrypsin (AAT)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Fazirsiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
August 2028 (1)
Phase 3Alpha-1 Antitrypsin DeficiencyRecruiting
Est. primary completion 2028-08-26 · NCT06165341 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Phase 3Alpha-1 Antitrypsin DeficiencyRecruiting
Est. primary completion 2029-01-17 · NCT05677971 · CT.gov ↗
What to watch
2033 (1)
May 2033 (1)
Phase 3Alpha-1 Antitrypsin DeficiencyActive not recruiting
Est. primary completion 2033-05-02 · NCT05899673 · CT.gov ↗
What to watch

See the full readout calendar ↗